CA2648594A1 - Solid oral dosage form containing an enhancer - Google Patents

Solid oral dosage form containing an enhancer Download PDF

Info

Publication number
CA2648594A1
CA2648594A1 CA002648594A CA2648594A CA2648594A1 CA 2648594 A1 CA2648594 A1 CA 2648594A1 CA 002648594 A CA002648594 A CA 002648594A CA 2648594 A CA2648594 A CA 2648594A CA 2648594 A1 CA2648594 A1 CA 2648594A1
Authority
CA
Canada
Prior art keywords
dosage form
composition
enhancer
bisphosphonate
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002648594A
Other languages
French (fr)
Other versions
CA2648594C (en
Inventor
Thomas W. Leonard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrion Research Ill Ltd
Original Assignee
Merrion Research Iii Limited
Thomas W. Leonard
Merrion Research Ii Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrion Research Iii Limited, Thomas W. Leonard, Merrion Research Ii Limited filed Critical Merrion Research Iii Limited
Publication of CA2648594A1 publication Critical patent/CA2648594A1/en
Application granted granted Critical
Publication of CA2648594C publication Critical patent/CA2648594C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

Claims (100)

1. A pharmaceutical composition which is effective in delivering therapeutically effective amounts of a drug and an enhancer, each as defined below, to an intestine, said composition comprising a bisphosphonate and an enhancer wherein the enhancer comprises a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms and is solid at room temperature.
2. The composition of claim 1, wherein the carbon chain length is from 8 to 14 carbon atoms.
3. The composition of claim 1 wherein the enhancer is a sodium salt of a medium chain fatty acid.
4. The composition of claim 3, wherein the enhancer is selected from the group consisting of sodium caprylate, sodium caprate, and sodium laurate.
5. The composition of claim 1, wherein the drug and the enhancer are present in a ratio of from 1:100,000 to 10:1 (drug:enhancer).
6. The composition of claim 1 further comprising at least one auxiliary excipient.
7. The composition of claim 1, wherein the bisphosphonate is selected from the group consisting of alendronate, clodronate, etidronate, incadronate, ibandronate, minodronate, neridronate, olpadronate, pamidronate, risedronate, tiludronate, and zoledronate.
8. A solid oral dosage form comprising the composition of claim 1 wherein the bisphosphonate and the enhancer in the dosage form are each present in therapeutically effective amounts.
9. The dosage form of claim 8, wherein the dosage form is a tablet, a capsule, or a multiparticulate.
10. The dosage form of claim 8, wherein the dosage form is a delayed release dosage form.
11. The dosage form of claim 8, wherein the dosage form is a tablet.
12. The dosage form of claim 11, wherein the tablet is a multilayer tablet.
13. The dosage form of claim 8, wherein the dosage form further comprises a rate-controlling polymer material.
14. The dosage form of claim 13, wherein the rate-controlling polymer material is HPMC.
15. The dosage form of claim 13, wherein the rate-controlling polymer material is a polymer derived from acrylic or methacrylic acid and their respective esters or copolymers derived from acrylic or methacrylic acid and their respective esters.
16. The dosage form of claim 13, wherein the composition is compressed into a tablet form prior to coating with the rate-controlling polymer material.
17. The dosage form of claim 16, wherein the tablet is a multilayer tablet.
18. The dosage form of claim 8, wherein the dosage form is a multiparticulate.
19. The dosage form of claim 18, wherein the multiparticulate comprises discrete particles, pellets, minitablets, or combinations thereof.
20. The dosage form of claim 19, wherein the multiparticulate comprises a blend of two or more populations of particles, pellets, minitablets, or combinations thereof each population having different in vitro or in vivo release characteristics.
21. The dosage form of claim 18, wherein the multiparticulate is encapsulated in a gelatin capsule.
22. The dosage form of claim 21, wherein the capsule is coated with a rate-controlling polymer material.
23. The dosage form of claim 18, wherein the multiparticulate is incorporated into a sachet.
24. The dosage form of claim 19, wherein the discrete particles, pellets, minitablets, or combinations thereof are compressed into a tablet.
25. The dosage form of claim 24, wherein the tablet is coated with a rate controlling polymer material.
26. The dosage form of claim 24, wherein the tablet is a multilayer tablet.
27. The dosage form of claim 25, wherein the tablet is a multilayer tablet.
28. The solid oral dosage form of claim 8, wherein the bisphosphonate and the enhancer are present in the dosage form in a ratio of from 1:100,000 to 10:1 (drug: enhancer).
29. The solid oral dosage form of claim 28, wherein the ratio is from 1:1,000 to 10:1 (drug:enhancer).
30. The solid oral dosage form of claim 8 comprising about 0.5 µg to about 1,000 mg of bisphosphonate.
31. The solid oral dosage form of claim 8, wherein the bisphosphonate is alendronate.
32. The solid oral dosage form of claim 8, wherein the bisphosphonate is risedronate.
33. The solid oral dosage form of claim 8, wherein the bisphosphonate is zoledronic acid.
34. The solid oral dosage form of claim 8, wherein the bisphosphonate is ibandronate.
35. The solid oral dosage form of claim 8, wherein the composition is in the form of a delayed release enteric coated tablet.
36. The solid oral dosage form of claim 35, wherein the bisphosphonate and the enhancer are present in the dosage form in a ratio of from 1:1,000 to 10:1 (drug:enhancer).
37. The solid oral dosage form of claim 35, wherein the enhancer is sodium caprate.
38. The solid oral dosage form of claim 29, wherein the bisphosphonate is alendronate.
39. The solid oral dosage form of claim 30, wherein the bisphosphonate is alendronate.
40. The solid oral dosage form of claim 29, wherein the bisphosphonate is risedronate.
41. The solid oral dosage form of claim 30, wherein the bisphosphonate is risedronate.
42. The solid oral dosage form of claim 29, wherein the bisphosphonate is zoledronic acid.
43. The solid oral dosage form of claim 30, wherein the bisphosphonate is zoledronic acid.
44. The solid oral dosage form of claim 29, wherein the bisphosphonate is ibandronate.
45. The solid oral dosage form of claim 30, wherein the bisphosphonate is ibandronate.
46. A pharmaceutical composition which is effective in delivering therapeutically effective amounts of a bisphosphonate and an enhancer to an intestine, said composition comprising a bisphosphonate and an enhancer, wherein the enhancer comprises:
(i) a salt of a medium chain fatty acid having a carbon chain length of from 6 to 20 carbon atoms;
(ii) a medium chain fatty acid halide derivative, a medium chain fatty acid anhydride derivative, or a medium chain fatty acid glyceride derivative, each of said derivatives having a carbon chain length of from 6 to 20 carbon atoms;
(iii) the fatty acid salt of clause (i) having, at the end opposite the fatty acid salt, an acid halide, acid anhydride, or glyceride moiety;
(iv) an acid halide derivative of clause (ii) above having, at the end opposite of the halide portion, an acid halide, acid anhydride, or glyceride moiety;
(v) an anhydride derivative of clause (ii) above having, at the end opposite of the anhydride, an acid anhydride, acid halide, or glyceride moiety;
or (vi) a glyceride derivative of clause (ii) above having, at the end opposite of the glyceride portion, a glyceride, acid halide, or acid anhydride moiety;
and wherein the enhancer is solid at room temperature.
47. A pharmaceutical composition which is effective in delivering therapeutically effective amounts of a bisphosphonate and an enhancer to an intestine, said composition comprising a bisphosphonate and an enhancer, wherein the enhancer: (1) comprises a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms; (2) is the only enhancer present in the composition; and (3) enhances intestinal delivery of the bisphosphonate to the underlying circulation.
48. The composition of claim 47, wherein the enhancer is a salt of a fatty acid having a carbon chain length of from 8 to 14 carbon atoms.
49. The composition of claim 48, wherein said fatty acid salt is a sodium salt.
50. The composition of claim 49, wherein said fatty acid salt is selected from the group consisting of sodium caprylate, sodium caprate, and sodium laurate.
51. The composition of claim 47, wherein the drug and the enhancer are present in a weight ratio of from 1:100000 to 10:1 (drug:enhancer).
52. The composition of claim 47, wherein the composition is in the form of a tablet, a capsule, or a multiparticulate.
53. The composition of claim 47, wherein the enhancer is selected from the group consisting of:
(a) an acid salt, acid halide, acid anhydride, or glyceride of a fatty acid having a carbon chain length of from 6 to 20 carbon atoms; and (b) a derivative of clause (a) which is a difunctional in that it has on the end of the carbon chain opposite the acid salt group an acid halide, an acid anhydride, or a glyceride moiety.
54. The composition of claim 47, wherein the composition is solid at room temperature.
55. The composition of claim 53, wherein the composition is solid at room temperature.
56. A process for the manufacture of a dosage form comprising the steps of:
a) providing a blend comprising a bisphosphonate and an enhancer which is solid at room temperature and enhances intestinal delivery of the bisphosphonate to the underlying circulation, wherein the enhancer comprises:
(i) a salt of a medium chain fatty acid having a carbon chain length of from 6 to 20 carbon atoms;
(ii) a medium chain fatty acid halide derivative, a medium chain fatty acid anhydride derivative, or a medium chain fatty acid glyceride derivative, each of said derivatives having a carbon chain length of from 6 to 20 carbon atoms;
(iii) the fatty acid salt of clause (i) having, at the end opposite the fatty acid salt, an acid halide, an acid anhydride, or glyceride moiety;
(iv) an acid halide derivative of clause (ii) above having, at the end opposite of the halide portion, an acid halide, acid anhydride, or glyceride moiety;
(v) an anhydride derivative of clause (ii) above having, at the end opposite of the anhydride, an acid anhydride, acid halide, or glyceride moiety; or (vi) a glyceride derivative of clause (ii) above having, at the end opposite of the glyceride portion, a glyceride, an acid halide, or acid anhydride moiety;
and b) forming the solid oral dosage form from the blend.
57. The process of claim 56, wherein the forming step comprises direct compression of the blend into a tablet.
58. The process of claim 56, wherein the forming step comprises granulating the blend to form a granulate for incorporation into said solid oral dosage form.
59. The process of claim 56, wherein the forming step comprises encapsulating the blend.
60. The process of claim 56, wherein the drag and the enhancer are blended in a ratio of from 1:100,000 to 10:1 (drug:enhancer).
61. A process of claim 56 further comprising the step of coating the solid oral dosage form with an enteric coating.
62. A method for the treatment or prevention of a medical condition comprising the step of administering orally to a patient a therapeutically effective amount of the composition of claim 1.
63. The method of claim 62, wherein the medical condition is osteoporosis.
64. The method of claim 62, wherein the medical condition is metastatic bone cancer.
65. The method of claim 62, wherein the medical condition is rheumatoid arthritis.
66. The method of claim 62, wherein the medical condition is a bone fracture.
67. The method of claim 62, wherein the administration step occurs within thirty minutes prior to the patient consuming food, medications, or beverages other than water.
68. The method of claim 62, wherein the administration step occurs at a time of day other than the morning.
69. The method of claim 62, wherein the administration step occurs in the evening.
70. The method of claim 62, wherein the administration occurs within 30 minutes prior to the patient lying down.
71. A method for the treatment or prevention of a medical condition comprising the step of administering orally to a patient a therapeutically effective amount of the composition of claim 47.
72. The method of claim 71, wherein the administration step occurs within thirty minutes prior to the patient consuming food, medications, or beverages other than water.
73. The method of claim 71, wherein the administration step occurs within 30 minutes prior to the patient consuming food, medications, or beverages other than water.
74. The method of claim 71, wherein the administration step occurs at a time of day other than the morning.
75. The method of claim 71, wherein the administration occurs within 30 minutes prior to the patient lying down.
76. A pharmaceutical composition comprising a bisphosphonate and an enhancer, wherein the enhancer enhances intestinal delivery of the bisphosphonate to the underlying circulation, and wherein the composition delivers a therapeutically effective amount of the bisphosphonate when administered to a patient within thirty minutes prior to the patient consuming food, medications, or beverages other than water.
77. An oral dosage form comprising the composition of claim 76.
78. A method for the treatment or prevention of a medical condition comprising the step of administering orally to a patient a therapeutically effective amount of the composition of claim 76.
79. A pharmaceutical composition comprising a bisphosphonate and an enhancer, wherein the enhancer enhances intestinal delivery of the bisphosphonate to the underlying circulation, and wherein the composition delivers a therapeutically effective amount of the bisphosphonate when administered to a patient at a time of day other than the morning.
80. An oral dosage form comprising the composition of claim 79.
81. A method for the treatment or prevention of a medical condition comprising the step of administering orally to a patient a therapeutically effective amount of the composition of claim 79.
82. A pharmaceutical composition comprising a bisphosphonate and an enhancer, wherein the enhancer enhances intestinal delivery of the bisphosphonate to the underlying circulation, and wherein the composition delivers a therapeutically effective amount of the bisphosphonate when administered to a patient within 30 minutes prior to the patient lying down.
83. An oral dosage form comprising the composition of claim 82.
84. A method for the treatment or prevention of a medical condition comprising the step of administering orally to a patient a therapeutically effective amount of the composition of claim 82.
85. A pharmaceutical composition comprising a bisphosphonate and an enhancer, wherein the enhancer enhances intestinal delivery of the bisphosphonate to the underlying circulation, and wherein the composition delivers a therapeutically effective amount of the bisphosphonate when administered to a patient within six hours after consuming food, medications, or beverages other than water.
86. An oral dosage form comprising the composition of claim 85.
87. A method for the treatment or prevention of a medical condition comprising the step of administering orally to a patient a therapeutically effective amount of the composition of claim 85.
88. A method for the prevention or treatment of osteoporosis comprising the step of administering orally to a patient a therapeutically effective amount of the composition of claim 1, wherein the administration step occurs weekly.
89. The method of claim 62, wherein about 1 mg to about 20 mg bisphosphonate is orally administered.
90. The method of claim 62, wherein about 2 mg to about 7 mg bisphosphonate is orally administered.
91. The method of claim 87, wherein about 1 mg to about 100 mg bisphosphonate is orally administered.
92. The method of claim 87, wherein about 1 mg to about 50 mg bisphosphonate is orally administered.
93. A pharmaceutical composition for oral administration which is effective in delivering therapeutically effective amounts of a drug and an enhancer to an intestine, said composition comprising alendronate and an enhancer, wherein the composition delivers a therapeutically effective amount of the alendronate when administered to a patient at bedtime.
94. A pharmaceutical composition for oral administration which is effective in delivering a therapeutically effective amounts of a drug and an enhancer to an intestine, said composition comprising alendronate and an enhancer, wherein the composition is effective in the prevention of osteoporosis with a weekly dose ofabout 1 to about 10 mg, a daily dose of about 0.1 to about 2 mg, or a monthly dose of about 3 to about 45 mg.
95. A pharmaceutical composition for oral administration which is effective in delivering therapeutically effective amounts of a drug and an enhancer to an intestine, said composition comprising alendronate and an enhancer, wherein the composition delivers a therapeutically effective amount of the alendronate when administered to a patient within six hours after consuming food, medications, or beverages other than water.
96. A pharmaceutical composition for oral administration which is effective in delivering therapeutically effective amounts of a drug and an enhancer to an intestine, said composition comprising alendronate and an enhancer, and wherein the composition is effective in the treatment of osteoporosis with a weekly dose of about 2 to 20 mg, a daily dose of about 0.2 to about 4mg, or a monthly dose of about 6 to about 90 mg.
97. A pharmaceutical composition for oral administration which is effective in delivering therapeutically effective amounts of a drug and an enhancer to an intestine, said composition comprising zoledronic acid and an enhancer.
98. The composition of claim 95, wherein the composition is effective in the treatment of bone cancer.
99. The composition of claim 95, wherein the composition is effective in the treatment or prevention of osteoporosis.
100. An oral dosage form comprising the composition of claim 95, wherein the dosage form comprises about 1 to about 25 mg zoledronic acid.
CA2648594A 2006-04-07 2007-04-09 Solid oral dosage form containing an enhancer Expired - Fee Related CA2648594C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79123106P 2006-04-07 2006-04-07
US60/791,231 2006-04-07
PCT/US2007/008935 WO2007117706A2 (en) 2006-04-07 2007-04-09 Solid oral dosage form containing an enhancer

Publications (2)

Publication Number Publication Date
CA2648594A1 true CA2648594A1 (en) 2007-10-18
CA2648594C CA2648594C (en) 2012-10-16

Family

ID=38581701

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2648594A Expired - Fee Related CA2648594C (en) 2006-04-07 2007-04-09 Solid oral dosage form containing an enhancer

Country Status (13)

Country Link
US (3) US7704977B2 (en)
EP (2) EP2526950A1 (en)
JP (3) JP5450052B2 (en)
KR (1) KR101191322B1 (en)
CN (2) CN101437522A (en)
AU (1) AU2007235251B2 (en)
BR (1) BRPI0710503A2 (en)
CA (1) CA2648594C (en)
ES (1) ES2426445T3 (en)
IL (1) IL194277A (en)
MX (1) MX2008012678A (en)
RU (1) RU2437662C2 (en)
WO (1) WO2007117706A2 (en)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CN101084016A (en) * 2004-04-15 2007-12-05 克艾思马有限公司 Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
AU2007235251B2 (en) 2006-04-07 2013-02-07 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd Solid oral dosage form containing an enhancer
AU2009244799B2 (en) 2008-05-07 2014-11-20 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
SI2343982T1 (en) 2008-09-17 2017-08-31 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
PL226261B1 (en) * 2008-12-31 2017-07-31 Univ Jagielloński Composition for the prolonged releasing of heparin and the application of the alginate hydroxypropyl cellulose gel for the prolonged releasing of heparin
AR075613A1 (en) * 2009-02-25 2011-04-20 Merrion Res Iii Ltd COMPOSITION AND SUPPLY OF BIFOSPHONATE DRUGS. TREATMENT METHOD
KR101673042B1 (en) 2009-03-12 2016-11-04 키바이오사이언스 아게 Treatment of diabetes and metabolic syndrome
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PT2459176T (en) 2009-07-31 2017-12-11 Gruenenthal Gmbh Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011028737A2 (en) * 2009-09-01 2011-03-10 Duke University Bisphosphonate compositions and methods for treating heart failure
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
FR2954320B1 (en) * 2009-12-17 2012-06-15 Cll Pharma SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
BR112013014940A2 (en) * 2010-12-15 2016-09-13 Merrion Reserarch Iii Ltd selective xa factor inhibitor pharmaceutical compositions for oral administration
US9278123B2 (en) 2010-12-16 2016-03-08 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
FR2975300B1 (en) * 2011-05-19 2013-06-07 Thierry Breul PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY
ES2673617T3 (en) 2011-11-02 2018-06-25 Keybioscience Ag Calcitonin mimetics to treat diseases and disorders
CN103998052B (en) 2011-11-02 2016-08-17 关键生物科学有限公司 For treating disease and disorderly peptide analogues
PL2827845T3 (en) 2012-03-22 2019-06-28 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
HRP20231060T1 (en) 2012-03-22 2023-12-22 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
HUE042757T2 (en) 2012-03-22 2019-07-29 Novo Nordisk As Compositions comprising a delivery agent and preparation thereof
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
ES2667535T3 (en) * 2012-05-14 2018-05-11 Antecip Bioventures Ii Llc Compositions comprising zoledronic acid or related compounds to relieve inflammatory pain and related conditions
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
ES2871328T3 (en) 2012-06-20 2021-10-28 Novo Nordisk As Tablet formulation comprising a peptide and a delivery agent
US20160193154A1 (en) * 2013-07-24 2016-07-07 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating
SI3321278T1 (en) 2013-11-14 2019-04-30 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
EP3250225A1 (en) * 2015-01-29 2017-12-06 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
WO2018226383A1 (en) * 2017-06-07 2018-12-13 Egy-Nano Pharma, Lp Oral prolonged drug delivery platforms
ES2960687T3 (en) 2018-02-02 2024-03-06 Novo Nordisk As Solid compositions comprising a GLP-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
CA3147641A1 (en) 2019-09-23 2021-04-01 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein b (apob) gene expression
US20220348908A1 (en) 2019-09-23 2022-11-03 Omega Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4alpha) GENE EXPRESSION
WO2021183720A1 (en) 2020-03-11 2021-09-16 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
CN113908155A (en) * 2021-10-29 2022-01-11 湖南师范大学 Fatty acid sodium salt auxiliary targeting medicine Sorafenib anti-liver cancer pharmaceutical composition

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB953626A (en) 1961-04-25 1964-03-25 Meito Sangyo Kk Enteric-coated tablets of dextran sulphate ester and method of preparation thereof
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS5973600A (en) 1982-10-19 1984-04-25 Okayasu Shoten:Kk Ovulatory inducing agent
JPS5973600U (en) 1982-11-10 1984-05-18 株式会社日立製作所 Variable stator vane drive mechanism
JPH0759502B2 (en) 1983-05-31 1995-06-28 チヨ−ン グツク ヤ−ン Dry direct compression composition for modified release dosage forms
DE3331009A1 (en) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen METHOD FOR INCREASING THE ENTERAL RESORBABILITY OF HEPARIN OR. HEPARINOIDS AND THE SO AVAILABLE HEPARIN OR HEPARINOID PREPARATION
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US4654155A (en) * 1985-03-29 1987-03-31 Reynolds Metals Company Microemulsion lubricant
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4764375A (en) * 1985-09-11 1988-08-16 Kv Pharmaceutical Company Sachet drug delivery system
US4786508A (en) * 1986-05-30 1988-11-22 Warner-Lambert Company Coated dosage forms
US4789547A (en) * 1987-06-17 1988-12-06 Warner-Lambert Company Transdermal matrix system
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5221734A (en) * 1987-10-01 1993-06-22 Ciba-Geigy Corporation Process for preparing a polypeptide growth factor for milk
GB2212396A (en) 1987-12-18 1989-07-26 Procter & Gamble Dietary supplement comprising calcium and delayed release coated iron
NO179479C (en) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Process for the preparation of an intravaginal pharmaceutical preparation
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
ZA898331B (en) 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
IL92537A (en) 1988-12-15 1994-04-12 Riker Laboratories Inc Topical formulations and transdermal delivery systems containing- isobutyl-1H-imidazo [4,5-c] quinolin-4-amine
GB2244015B (en) 1990-03-14 1993-10-27 Hadley Sections Limited Tube and method of forming same
JPH03275633A (en) 1990-03-23 1991-12-06 Teikoku Seiyaku Co Ltd Absorbefacient for physiologically active polypeptide
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
JPH04149126A (en) 1990-10-09 1992-05-22 Mitsubishi Kasei Corp Pharmaceutical composition for transmucous administration
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
IT1245761B (en) 1991-01-30 1994-10-14 Alfa Wassermann Spa PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLICANS ABSORBABLE ORALLY.
US5744450A (en) * 1991-03-14 1998-04-28 The Salk Institute For Biological Studies GnRH analogs
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
DK0580778T3 (en) * 1991-04-19 2000-01-31 Lds Technologies Inc Convertible microemulsion formulations
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
ATE195075T1 (en) 1991-11-22 2000-08-15 Procter & Gamble Pharma DELAYED-RELEASE MEDICINAL PRODUCTS CONTAINING RISEDRONATE
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
SE501389C2 (en) 1992-04-24 1995-01-30 Leiras Oy Pharmaceutical preparation and process for its preparation
DE4317458A1 (en) * 1992-06-11 1993-12-16 Bayer Ag Use of cyclic depsipeptides with 18 ring atoms for the control of endoparasites, new cyclic depsipeptides with 18 ring atoms and process for their preparation
JP3190441B2 (en) 1992-07-20 2001-07-23 エーザイ株式会社 Stable formulation containing azelastine hydrochloride
RU2068689C1 (en) 1992-09-24 1996-11-10 Товарищество с ограниченной ответственностью "Лекрон" Method of paracetamol tablet producing
KR0157280B1 (en) 1992-11-06 1998-11-16 나까토미 히로타카 Oral pharmaceutical preparation release in the lower digestive tract
JPH06192107A (en) 1992-12-25 1994-07-12 Sanwa Kagaku Kenkyusho Co Ltd Glycyrrhizin oral agent
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
SE9302135D0 (en) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab NEW PHARMACEUTICAL COMPOSITION
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
ES2068762B1 (en) * 1993-07-21 1995-12-01 Lipotec Sa A NEW PHARMACEUTICAL PREPARATION TO IMPROVE THE BIOAVAILABILITY OF DRUGS OF DIFFICULT ABSORPTION AND PROCEDURE FOR THEIR OBTAINING.
ATE317397T1 (en) * 1993-11-17 2006-02-15 Athena Neurosciences Inc TRANSPARENT LIQUID FOR ADMINISTRATION OF ENCAPSULATED MEDICATIONS
DE69530973T2 (en) 1994-02-16 2004-05-19 Abbott Laboratories, Abbott Park METHOD FOR PRODUCING FINE-PART PHARMACEUTICAL FORMULATIONS
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
IL110024A (en) 1994-06-15 1998-04-05 Yissum Res Dev Co Controlled release oral drug delivery system containing hydrogel- forming polymer
GB9414318D0 (en) * 1994-07-15 1994-09-07 Dowelanco Ltd Preparation of aqueous emulsions
PT742011E (en) * 1994-11-17 2002-10-31 Toray Industries PREPARATION THAT MAY BE ABSORBED BY PERCUTANEOUS VIA
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2220451A1 (en) * 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Methods and compositions for improving digestion and absorption in the small intestine
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5807983A (en) * 1995-12-28 1998-09-15 The Salk Institute For Biological Studies GNRH antagonist betides
DE69726879T2 (en) 1996-05-17 2004-10-14 Merck & Co., Inc. BIPHOSPHONATE FORMULATION WITH EFFECT
US6150522A (en) 1996-05-20 2000-11-21 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6147088A (en) 1996-05-20 2000-11-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1997044339A1 (en) 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
GB9614235D0 (en) 1996-07-06 1996-09-04 Danbiosyst Uk Composition for enhanced uptake of polar drugs from mucosal surfaces
WO1998018417A1 (en) * 1996-10-30 1998-05-07 Theratech, Inc. Fatty acid esters of lactic acid salts as permeation enhancers
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US6156772A (en) 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6156767A (en) 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6004984A (en) 1997-06-05 1999-12-21 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5981550A (en) * 1997-06-05 1999-11-09 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
IL121269A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Compositions and methods for reversibly increasing permeability of biomembranes
IL121268A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
JP4181232B2 (en) 1997-07-18 2008-11-12 帝國製薬株式会社 Diclofenac sodium-containing oily external patch preparation
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
SE9703691D0 (en) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
US6017944A (en) * 1997-10-28 2000-01-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE69910183T2 (en) * 1998-03-11 2004-06-03 Grelan Pharmaceutical Co., Ltd., Hamura COLONELY SPIRLING COMPOSITIONS
US5998432A (en) 1998-04-02 1999-12-07 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6025366A (en) * 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6077847A (en) * 1998-04-02 2000-06-20 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6270804B1 (en) * 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
JP3853985B2 (en) * 1998-08-03 2006-12-06 有限会社 健康百二十才 Disinfectant containing iron ions
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
AU2681300A (en) * 1999-02-22 2000-09-14 Elan Corporation, Plc Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
SE9901272D0 (en) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
JP2001081031A (en) * 1999-08-30 2001-03-27 Schering Ag Benzamide derivative-containing preparation having improved solubility and oral adsorption
DE60033453T2 (en) 1999-12-08 2007-11-29 Cyclacel Pharmaceuticals Inc. Use of depsipeptides and their analogues as immunosuppressants for the treatment of infectious diseases, autoimmune diseases, allergies and hyperproliferative skin diseases
US20020002140A1 (en) * 2000-01-14 2002-01-03 Holick Michael F. Novel bisphosphonates and uses thereof
EP1267890A2 (en) * 2000-04-07 2003-01-02 The Board of Regents of The University of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
IT1318539B1 (en) 2000-05-26 2003-08-27 Italfarmaco Spa PROLONGED RELEASE PHARMACEUTICAL COMPOSITIONS FOR THE PARENTERAL ADMINISTRATION OF BIOLOGICALLY HYDROPHILE SUBSTANCES
CN1141974C (en) 2000-06-07 2004-03-17 张昊 Colon-releasing oral biological preparation
IL153229A0 (en) * 2000-06-20 2003-07-06 Novartis Ag Method of administering bisphosphonates
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US6379960B1 (en) * 2000-12-06 2002-04-30 Isis Pharmaceuticals, Inc. Antisense modulation of damage-specific DNA binding protein 2, p48 expression
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
EP1390048A2 (en) * 2001-02-16 2004-02-25 Shimizu Pharmaceutical Co., Ltd. Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
MXPA03007837A (en) * 2001-03-01 2004-03-16 Emisphere Techonologies Inc Compositions for delivering bisphosphonates.
HUP0400096A2 (en) * 2001-05-02 2004-04-28 Novartis Ag. Pharmaceutical uses of bisphosphonates
WO2002092070A1 (en) 2001-05-11 2002-11-21 Elan Corporation, Plc Isostearic acid salts as permeation enhancers
CA2452056C (en) 2001-07-02 2011-11-01 Elan Corporation, Plc. Compositions of bioactive material particles dispersed in a continuous solid encapsulating material
US20030031757A1 (en) 2001-08-03 2003-02-13 Kraft Food Holdings, Inc. Stable and bioavailable iron fortified beverages
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
DE10157628A1 (en) 2001-11-26 2003-06-12 Zentaris Ag Solution for injection of an LHRH antagonist
US7214662B2 (en) * 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
WO2003047493A2 (en) 2001-12-03 2003-06-12 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
CA2468687A1 (en) 2001-12-13 2003-06-26 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
CA2471096A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
ATE477810T1 (en) 2002-02-28 2010-09-15 Nipro Corp STABILIZED ALBUMIN PREPARATIONS
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
BR0308901A (en) * 2002-05-10 2005-01-04 Hoffmann La Roche bisphosphonic acids for osteoporosis treatment and prevention
US7154002B1 (en) * 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005020913A2 (en) * 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
EP1667691A1 (en) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
AU2004285535A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE10358525A1 (en) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasiticides Means for topical application
AR046773A1 (en) 2003-12-23 2005-12-21 Novartis Ag PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATES
WO2005062041A1 (en) * 2003-12-24 2005-07-07 Astrazeneca Ab Pharmaceutical dissolution testing using a non-ionic surfactant
US7606313B2 (en) * 2004-01-15 2009-10-20 Ittiam Systems (P) Ltd. System, method, and apparatus for error concealment in coded video signals
JPWO2005072747A1 (en) 2004-02-02 2007-09-13 小野薬品工業株式会社 Bone resorption inhibitor
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
CN101084016A (en) * 2004-04-15 2007-12-05 克艾思马有限公司 Compositions capable of facilitating penetration across a biological barrier
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
KR20080083068A (en) * 2004-05-24 2008-09-12 더 프록터 앤드 갬블 캄파니 Enteric solid oral dosage form of bisphosphonate containing a chelating agent
CA2574085C (en) 2004-07-16 2014-02-11 Oakwood Laboratories, L.L.C. Gonadotropin releasing hormone antagonists
EP1773878B1 (en) * 2004-07-19 2015-03-04 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
JP4965446B2 (en) * 2004-08-31 2012-07-04 ノヴォ ノルディスク アー／エス Use of tris (hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
EP1674082A1 (en) 2004-12-22 2006-06-28 Zentaris GmbH Process for the manufacture of sterile suspensions or lyophilisates of low-soluble basic peptide complexes, pharmaceutical formulations comprising these complexes and their use as medicament
WO2006102117A1 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
IL174387A0 (en) 2005-03-31 2008-01-20 Dexcel Pharma Technologies Ltd A solid composition for intra-oral delivery of insulin
WO2006103657A2 (en) 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. A solid composition for intra-oral delivery of insulin
WO2006116565A2 (en) 2005-04-25 2006-11-02 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
NZ563271A (en) * 2005-04-29 2009-12-24 Cubist Pharm Inc Therapeutic compositions
WO2006125762A1 (en) * 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
CA2612508A1 (en) * 2005-06-17 2006-12-28 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
US20070021378A1 (en) * 2005-07-22 2007-01-25 The Regents Of The University Of California Heparin compositions and selectin inhibition
US20070077313A1 (en) * 2005-10-04 2007-04-05 U.S. Pharmaceutical Corporation Toleration iron supplement compositions
AU2007235251B2 (en) 2006-04-07 2013-02-07 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd Solid oral dosage form containing an enhancer
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CN101125132A (en) 2007-07-25 2008-02-20 司炳奎 Oral insulin enteric capsule and its preparation method
AU2009244799B2 (en) 2008-05-07 2014-11-20 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
SI2343982T1 (en) * 2008-09-17 2017-08-31 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
AR075613A1 (en) 2009-02-25 2011-04-20 Merrion Res Iii Ltd COMPOSITION AND SUPPLY OF BIFOSPHONATE DRUGS. TREATMENT METHOD
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration

Also Published As

Publication number Publication date
AU2007235251B2 (en) 2013-02-07
KR101191322B1 (en) 2012-10-16
EP2007397A2 (en) 2008-12-31
JP2014037412A (en) 2014-02-27
ES2426445T3 (en) 2013-10-23
US8883203B2 (en) 2014-11-11
RU2437662C2 (en) 2011-12-27
US8883201B2 (en) 2014-11-11
CA2648594C (en) 2012-10-16
AU2007235251A2 (en) 2008-11-06
EP2526950A1 (en) 2012-11-28
IL194277A (en) 2014-01-30
CN101437522A (en) 2009-05-20
MX2008012678A (en) 2008-12-17
US20070238707A1 (en) 2007-10-11
US20100247640A1 (en) 2010-09-30
KR20090037851A (en) 2009-04-16
JP2009533349A (en) 2009-09-17
EP2007397A4 (en) 2010-03-10
EP2007397B1 (en) 2013-07-24
JP2016040301A (en) 2016-03-24
IL194277A0 (en) 2009-09-22
JP5450052B2 (en) 2014-03-26
CN105232482A (en) 2016-01-13
WO2007117706A3 (en) 2008-10-16
AU2007235251A1 (en) 2007-10-18
RU2008144136A (en) 2010-05-20
US7704977B2 (en) 2010-04-27
US20100022480A1 (en) 2010-01-28
WO2007117706A2 (en) 2007-10-18
BRPI0710503A2 (en) 2011-08-16

Similar Documents

Publication Publication Date Title
CA2648594A1 (en) Solid oral dosage form containing an enhancer
US20180153914A1 (en) Treatment of pain with oral dosage forms comprising zoledronic acid and an enhancer
TWI480286B (en) Composition and drug delivery of bisphosphonates
JP4471498B2 (en) Compositions containing diphosphonic acid
RU2193881C2 (en) Pharmaceutical ibandronate-containing preparation for oral usage
JP4605221B2 (en) Enteric and solid oral dosage forms of bisphosphonates containing chelating agents
AU2003229770B2 (en) Bisphosphonic acid for the treatment and prevention of osteoporosis
US20080153785A1 (en) Pharmaceutical Compositions Containing Biophosphonate for Improving Oral Absorption
KR100482931B1 (en) Oral pharmaceutical preparation containing ibandronat
MXPA01003435A (en) Compositions containing diphosphonic acids

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170410